MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas

Leukemia

Volumn 29, Issue 9, 2015, Pages 1868-1874

  Jeong, D ^a   Kim, J ^a   Nam, J ^a   Sun, H ^a   Lee, Y H ^b   Lee, T J ^c   Aguiar, R C T ^d,e   Kim, S W ^a  

^a Pusan National University   (South Korea)

^b Yonsei University   (South Korea)

^c Yeungnam University   (South Korea)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 124; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA; 3' UNTRANSLATED REGION; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MIRN124 MICRORNA, HUMAN;

ARTICLE; B CELL LYMPHOMA; B-CELL LYMPHOMA CELL LINE; CANCER PROGNOSIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STABLE EXPRESSION; TRANSIENT EXPRESSION; 3' UNTRANSLATED REGION; APOPTOSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR CLONING; ONCOGENE MYC; PROTO ONCOGENE; REPORTER GENE; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLONING, MOLECULAR; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, MYC; GENES, REPORTER; HUMANS; LYMPHOMA, B-CELL; MICRORNAS; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940792557     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.101     Document Type: Article

References (28)

1. Di Lisio L, Martinez N, Montes-Moreno S, Piris-Villaespesa M, Sanchez-Beato M, Piris MA. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 2012; 120: 1782-1790.
2. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362: 1417-1429.
3. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106: 1164-1174.
4. Reeder CB, Ansell SM. Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 2011; 117: 1453-1462.
5. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ et al. Double-hit B-cell lymphomas. Blood 2011; 117: 2319-2331.
6. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3460-3467.
7. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3452-3459.
8. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121: 4021-4031, quiz 4250.
9. Li C, Kim SW, Rai D, Bolla AR, Adhvaryu S, Kinney MC et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 2009; 113: 6681-6690.
10. An L, Liu Y, Wu A, Guan Y. MicroRNA-124 inhibits migration and invasion by down-regulating ROCK1 in glioma. PLoS One 2013; 8: e69478.
11. Lu Y, Yue X, Cui Y, Zhang J, Wang K. MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun 2013; 441: 873-879.
12. Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y et al. MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS One 2013; 8: e70300.
13. Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 2011; 6: e19027.
14. Ning BF, Ding J, Liu J, Yin C, Xu WP, Cong WM et al. Hepatocyte nuclear factor 4alpha-nuclear factor-kappaB feedback circuit modulates liver cancer progression. Hepatology 2014; 60: 1607-1619.
15. Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 2012; 28: 128-136.
16. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012; 12: 613-626.
17. Asuthkar S, Stepanova V, Lebedeva T, Holterman AL, Estes N, Cines DB et al. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell 2013; 24: 2620-2632.
18. Liu X, Li F, Zhao S, Luo Y, Kang J, Zhao H, et al. MicroRNA-124-mediated regulation of inhibitory member of apoptosis-stimulating protein of p53 family in experimental stroke. Stroke 2013; 44: 1973-1980.
19. Xie L, Zhang Z, Tan Z, He R, Zeng X, Xie Y et al. MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. Mol Cell Biochem 2014; 392: 153-159.
20. Kim SW, Rai D, Aguiar RC. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma. Clin Cancer Res 2011; 17: 6723-6732.
21. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 2012; 109: 7865-7870.
22. Kim SW, Rai D, McKeller MR, Aguiar RC. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. Blood 2009; 113: 6153-6160.
23. Ortega M, Bhatnagar H, Lin AP, Wang L, Aster JC, Sill H et al. A microRNAmediated regulatory loop modulates NOTCH and MYC oncogenic signals in Band T-cell malignancies. Leukemia 2014; 29: 968-976.
24. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood 2013; 122: 3884-3891.
25. Tracey L, Perez-Rosado A, Artiga MJ, Camacho FI, Rodriguez A, Martinez N et al. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005; 206: 123-134.
26. Duyao MP, Buckler AJ, Sonenshein GE. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sci USA 1990; 87: 4727-4731.
27. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1: 45-49.
28. Hunten S, Siemens H, Kaller M, Hermeking H. The p53/microRNA network in cancer: experimental and bioinformatics approaches. Adv Exp Med Biol 2013; 774: 77-101.